AstraZeneca plc (AZN.L, AZN) and MedImmune, its global biologics research and development arm, said that the U.S. Food and Drug Administration or FDA has granted Breakthrough Therapy Designation for Imfinzi (durvalumab) for the treatment of patients with locally-advanced, unresectable non-small cell lung cancer or NSCLC whose disease has not progressed following platinum-based chemoradiation therapy.
from RTT - Biotech http://ift.tt/2tQ4bSS
via IFTTT
No comments:
Post a Comment